The short version of peptide backbone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-21 and is reviewed periodically as new material appears.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Singapore and Sri Lanka. ISCEA's Certified Lean Master (CLM) programme is delivered in Hong Kong and Malaysia through SGS, the global inspection, verification, testing and certification entity. In 2019 Tim Charlton was appointed to the position of President of ISCEA-Pacific (Australia and New Zealand) and also appointed to the ISCEA- APAC Board that included Mr. Ejazur Rahman (Bangladesh) CEO, ISCEA-Asia, Mr. Nikhil Oswal (India), CEO, ISCEA-India, Dr. Premkumar Rajagopal (Malaysia), President, MUST (Malaysia University of Science and Technology), Mr. Sandeep Chatterjee (India), Senior Manager, Deloitte India, Dr. Nyoman Pujawan, Ph.D., (Indonesia), Professor, Institut Teknologi Sepuluh Nopember, and Dr. Harish Pant (India), Chief Business Transformation Officer, NTF (India) Pvt. Ltd. In 2024, ISCEA started a partnership with Singapore-based SCALA - Supply Chain and Logistics Academy. SCALA (Singapore) and PPLC Superport & Industrial Co., LTD. (Cambodia) signed a historic Memorandum of Understanding (MoU) to train up to 300 Cambodian trainees in Singapore. The training included hands-on experiential learning and certification as Certified Supply Chain Analysts from ISCEA. The MoU signing was further marked at the Cambodia-Singapore Business Forum in the presence of Samdech Moha Borvor Thipadei Hun Manet, Prime Minister of the Kingdom of Cambodia.
Middleton is dyslexic. He read from the New Revised Standard Version of the Bible at the 2011 wedding of his sister Catherine to Prince William. In 2019, he disclosed his struggles with depression and attention deficit hyperactivity disorder, which he attributed to public scrutiny from age 23 as a result of his eldest sister's relationship. He sought treatment in 2017, undertaking cognitive behavioral therapy. Middleton also spent "restorative time" at the Glen Affric Estate, where he has hosted deer-stalking parties. The estate is owned by his sister Philippa's father-in-law. In the same year, he penned a column in the Daily Mail about mental health. Middleton is an ambassador for the Pets As Therapy charity and has credited his dog, Ella, for helping him through his depression. He breeds dogs, owning six, as well as one rescue lamb. Middleton also keeps bees on the grounds of Bucklebury Manor. In April 2020, he founded the Paw Print Fund in aid of animal welfare charities. Middleton was in a relationship with actress Donna Air from 2013 to 2018. Middleton met French financial analyst Alizée Thevenet (b. 30 November 1989) in 2018. She is the daughter of retired diplomat Jean-Gabriel Thevenet. Middleton and Alizée announced their engagement in September 2019. On 11th September 2021, Alizée's mother, along with James's family, attended the wedding in the village of Bormes-les-Mimosas in the south of France where Alizée's family lives. Alizée's father had died some months before the wedding.
=== Perioperative === Perioperative hyperglycemia has been associated with immunosuppression, increased infections, osmotic diuresis, delayed wound healing, delayed gastric emptying, sympatho-adrenergic stimulation, and increased mortality. In addition, it reduces skin graft success, exacerbates brain, spinal cord, and renal damage by ischemia, worsens neurologic outcomes in traumatic head injuries, and is associated with postoperative cognitive dysfunction following CABG.
=== Infertility === Infertility, not very well understood, posed serious social and cultural repercussions. The seventh-century scholar Sun Simiao is often quoted: "those who have prescriptions for women's distinctiveness take their differences of pregnancy, childbirth and [internal] bursting injuries as their basis." Even in contemporary fuke placing emphasis on reproductive functions, rather than the entire health of the woman, suggests that the main function of fuke is to produce children. Once again, the kidney visceral system governs the "source Qi", which governs the reproductive systems in both sexes. This source Qi was thought to "be slowly depleted through sexual activity, menstruation and childbirth." It was also understood that the depletion of source Qi could result from the movement of an external pathology that moved through the outer visceral systems before causing more permanent damage to the home of source Qi, the kidney system. In addition, the view that only very serious ailments ended in the damage of this system means that those who had trouble with their reproductive systems or fertility were seriously ill. According to traditional Chinese medical texts, infertility can be summarized into different syndrome types. These were spleen and kidney depletion (yang depletion), liver and kidney depletion (yin depletion), blood depletion, phlegm damp, liver oppression, and damp heat. This is important because, while most other issues were complex in Chinese medical physiology, women's fertility issues were simple.
== Bibliography == "Hudson River Chain", Harper's Encyclopedia of United States History, Vol. IV, p. 447, Harper & Brothers Publishers, 1905. Information plaques at Trophy Point at West Point, New York. "West Point Fortifications", Scribd U.S. Military Academy Department of History, West Point Fortifications Staff Ride Notecards, second edition (1998)
Sources: en.wikipedia.org
Cancer begins as cells that grow uncontrollably, usually as a result of an internal change or oncogenic mutations within the cell. Cancer develops and progresses as the microenvironment undergoes dynamic changes. The stromal reaction in cancer is similar to the stromal reaction induced by injury or wound repair: increased extracellular matrix (ECM) and growth factor production and secretion, which consequently cause growth of the tissue. In other words, the body reacts similarly to a cancer as it does to a wound, causing scar-like tissue to be built around the cancer. As such, the surrounding stroma plays a very important role in the progression of cancer. The interaction between cancer cells and surrounding tumor stroma is thus bidirectional, and the mutual cellular support allows for the progression of the malignancy.
== Episode 5: A Question of Trust == Lashay Hamblin is a 16-year-old high school student at the time of filming the episode. She suffers from an illness with similarities to Bulimia, only she has no control over her actions. Everything that Lashay eats or drinks is almost immediately thrown up and she had very bad stomach cramping because of it. She expresses her bad experience with physicians who did not want to diagnose her because at only 16 years old she shows an almost exact reflection of an eating disorder. During her adolescence in 2014 her family went on a trip to Costa Rica where she had an encounter with a wild raccoon that tore at her skin. When she got back home from the trip only two days later she had severe symptoms of vomiting, headaches, neck pains and stomach pains. At first physicians thought it was rabies and immediately gave her the rabies vaccination, this however made everything extremely worse and all her symptoms progressed. Since that day in the emergency room she has yet to recover or improve from any of the symptoms. She's not able to walk straight up, sit in a chair, and has a constant throbbing headache. Due to her conditions doctors decided to implant a chest port to be able to provide her with the nutrients and hydration she needs to survive. One physician the family met with suggested she might have a Cerebral Spinal Fluid Leak that would only explain her constant headaches and dizziness.
A language model may associate certain professions with specific genders if such patterns are prevalent in the data. Similarly, some image generation systems have been observed to generate images of men as CEOs more often than women. AI software, when using voice recognition software in particular, struggles to recognize and understand speech impediments. For example, people with a stutter struggle to activate voice-activated assistants such as Gemini and Siri due to how the software was trained. Companies that use AI systems to hire for new positions also filter out people with accents and speech due to voice recognition software incorrectly transcribing how candidates speak during the interview process. Because of this, people with disabilities and uncommon accents don't often make it to a human interviewer when these generative AI systems are used. This is due to many AI models being trained and produced in the United States, and therefore, off of American accents.
== Interactions == As ribociclib is mainly metabolized by the liver enzyme CYP3A4, inhibitors of this enzyme increase its concentrations in the body and could potentiate side effects and toxicity. Examples of such inhibitors include ketoconazole and similar antifungal drugs, ritonavir, clarithromycin, as well as grapefruit. Conversely, drugs that induce CYP3A4, such as rifampicin and St John's Wort, can decrease ribociclib concentrations. Ribociclib itself is a moderate to strong CYP3A4 inhibitor and can increase concentrations of other drugs that share this metabolism, as has been shown with midazolam. It also inhibits a number of transporter proteins and could thus theoretically interfere with the transport of other drugs in the body. It could also amplify QT prolongation of other drugs such as antiarrhythmics, clarithromycin, and haloperidol.
Sources: en.wikipedia.org
According to the first option, the spent nuclear fuel is considered complete waste. After an interim storage (wet and dry), all the used fuel is directly disposed of in a deep geological repository. Several geological media and repository designs are being studied according to different natures of fuel and their burnup, radioactive inventory and decay heat generation. The assessment of a geological disposal is based on the multi-barrier approach, which combines multiple effects of engineered and natural barriers in order to delay potential long-lived radionuclide migrations to the biosphere over time. Reprocessing is the alternative option for the spent fuel after a long interim storage. The used fuel is not considered waste anymore but a future energy resource. A large amount of fertile uranium (
=== Dry instant soups === Sometimes ingredients used in dry instant soups are ground into fragments, which enables them to be dissolved when water is added. These particulates are sometimes prepared using freeze-drying and puff drying. Freeze-drying is a recent dehydration breakthrough method that is restricted to high-value foods due to the high cost associated with the process. Despite its cost, freeze-drying is very effective in retaining the overall quality and nutritional value of the food through a process called sublimation, where water is removed (evaporated) from food in its frozen state without the transition through the liquid state. Removing water from food prevents spoilage as it does not give an environment that favors the growth of spoilage-causing microorganisms such as bacteria, mould, and yeast. Freeze-drying also reduces the total weight of the food, especially fruit and vegetables that are mostly water, thus making the transportation of these products more efficient. Vegetables used in instant soup mixes often undergo freeze-drying which helps them retain their nutritional value, texture, and flavor. Furthermore, as the food remains rigid during dehydration, subliming water creates holes where the evaporated ice crystals used to be. This allows freeze-dried foods such as vegetables to retain their shape without shrinkage, and these foods rehydrate completely when water is added to the mix that fills the voids left by the subliming water.
In an experiment by Hanson et al. that was published in 2006, the amount of harmful reactive oxygen species (ROS) was measured in untreated and in sunscreen treated skin. In the first 20 minutes, the film of sunscreen had a protective effect and the number of ROS species was smaller. After 60 minutes, however, the amount of absorbed sunscreen was so high that the amount of ROS was higher in the sunscreen-treated skin than in the untreated skin. The study indicates that sunscreen must be reapplied within 2 hours in order to prevent UV light from penetrating to sunscreen-infused live skin cells.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.